Cellular immunotherapy of cancer: an overview and future directions

被引：15

作者：

Tao, Ziqi ^{[1
]}

Li, Shuang ^{[2
]}

Ichim, Thomas E. ^{[3
]}

Yang, Junbao ^{[4
]}

Riordan, Neil ^{[5
]}

Yenugonda, Venkata ^{[4
]}

Babic, Ivan ^{[4
]}

Kesari, Santosh ^{[4
,6
]}

机构：

[1] Southeast Univ, Nanjing Univ Chinese Med, Affiliated XuZhou Ctr Hosp, Affiliated XuZhou Hosp,Med Coll, Nanjing, Jiangsu, Peoples R China

[2] Dalian Univ, Affiliated Zhongshan Hosp, Dept Endocrinol, Dalian, Peoples R China

[3] Immune Advisors LLC, San Diego, CA 92122 USA

[4] Providence St Johns Hlth Ctr, John Wayne Canc Inst, Pacific Neurosci Inst, Dept Translat Neurosci & Neurotherapeut, Santa Monica, CA 90404 USA

[5] Medistem Panama Inc, City Of Knowledge, Clayton, Panama

[6] John Wayne Canc Inst, 2200 Santa Monica Blvd, Santa Monica, CA 90404 USA

来源：

IMMUNOTHERAPY | 2017年 / 9卷 / 07期

关键词：

cancer; CAR T-cells; cellular therapy; immunotherapy; NR2F6; TUMOR-INFILTRATING LYMPHOCYTES; PULSED DENDRITIC CELLS; PHASE-II TRIAL; CHRONIC MYELOID-LEUKEMIA; ACTIVATED KILLER-CELLS; CYTOTOXIC T-CELLS; DONOR LEUKOCYTE INFUSIONS; HEPATOCELLULAR-CARCINOMA PATIENTS; ANTIGEN-PROCESSING MACHINERY; METASTATIC MELANOMA PATIENTS;

D O I：

10.2217/imt-2016-0086

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The clinical success of checkpoint inhibitors has led to a renaissance of interest in cancer immunotherapies. In particular, the possibility of ex vivo expanding autologous lymphocytes that specifically recognize tumor cells has attracted much research and clinical trial interest. In this review, we discuss the historical background of tumor immunotherapy using cell-based approaches, and provide some rationale for overcoming current barriers to success of autologous immunotherapy. An overview of adoptive transfer of lymphocytes, tumor infiltrating lymphocytes and dendritic cell therapies is provided. We conclude with discussing the possibility of gene-manipulating immune cells in order to augment therapeutic activity, including silencing of the immune-suppressive zinc finger orphan nuclear receptor, NR2F6, as an attractive means of overcoming tumor-associated immune suppression.

引用

页码：589 / 606

页数：18

共 245 条

[51] Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-α results in the activation of specific CD8+ T cells and monocyte/dendritic cell precursors
Di Pucchio, Tiziana
Pilla, Lorenzo
Capone, Imerio
Ferrantini, Maria
Montefiore, Enrica
Urbani, Francesca
Patuzzo, Roberto
Pennacchioli, Elisabetta
Santinami, Mario
Cova, Agata
Sovena, Gloria
Arienti, Flavio
Lombardo, Claudia
Lombardi, Arianna
Caporaso, Patrizia
D'Atri, Stefania
Marchetti, Paolo
Bonmassar, Enzo
Parmiani, Giorgio
Belardelli, Filippo
Rivoltini, Licia
[J]. CANCER RESEARCH, 2006, 66 (09) : 4943 - 4951
[52] THE CLINICAL-EXPERIENCE WITH INTERLEUKIN-2 IN CANCER-THERAPY
DILLMAN, RO
[J]. CANCER BIOTHERAPY, 1994, 9 (03): : 183 - 209
[53] Tumor Stem Cell Antigens as Consolidative Active Specific Immunotherapy: A Randomized Phase II Trial of Dendritic Cells Versus Tumor Cells in Patients With Metastatic Melanoma
Dillman, Robert O.
Cornforth, Andrew N.
DePriest, Carol
McClay, Edward F.
Amatruda, Thomas T.
de Leon, Cristina
Ellis, Robin E.
Mayorga, Cheryl
Carbonell, Denysha
Cubellis, James M.
[J]. JOURNAL OF IMMUNOTHERAPY, 2012, 35 (08) : 641 - 649
[54] Phase II Trial of Dendritic Cells Loaded with Antigens from Self-Renewing, Proliferating Autologous Tumor Cells as Patient-Specific Antitumor Vaccines in Patients with Metastatic Melanoma: Final Report
Dillman, Robert O.
Selvan, Senthamil R.
Schiltz, Patric M.
McClay, Edward F.
Barth, Neil M.
DePriest, Carol
de Leon, Cristina
Mayorga, Cheryl
Cornforth, Andrew N.
Allen, Kanoe
[J]. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2009, 24 (03) : 311 - 319
[55] Immunotherapy by autologous dendritic cell vaccine in patients with advanced HCC
El Ansary, Mervat
Mogawer, Sherif
Abd Elhamid, Samah
Alwakil, Sahr
Aboelkasem, Fatma
El Sabaawy, Hatem
Abdelhalim, Olfat
[J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2013, 139 (01) : 39 - 48
[56] Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial
Ellebaek, Eva
Engell-Noerregaard, Lotte
Iversen, Trine Zeeberg
Froesig, Thomas Moerch
Munir, Shamaila
Hadrup, Sine Reker
Andersen, Mads Hald
Svane, Inge Marie
[J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2012, 61 (10) : 1791 - 1804
[57] Phase I trial of preoperative intratumoral injection of immature dendritic cells and OK-432 for resectable pancreatic cancer patients
Endo, Hisahito
Saito, Takuro
Kenjo, Akira
Hoshino, Mika
Terashima, Masanori
Sato, Tetsu
Anazawa, Takayuki
Kimura, Takashi
Tsuchiya, Takao
Irisawa, Atsushi
Ohira, Hiromasa
Hikichi, Takuto
Takagi, Tadayuki
Gotoh, Mitsukazu
[J]. JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, 2012, 19 (04) : 465 - 475
[58] Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters
Engell-Noerregaard, Lotte
Hansen, Troels Holz
Andersen, Mads Hald
Straten, Per Thor
Svane, Inge Marie
[J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2009, 58 (01) : 1 - 14
[59] Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients
Escobar, A
López, M
Serrano, A
Ramirez, M
Pérez, C
Aguirre, A
González, R
Alfaro, J
Larrondo, M
Fodor, M
Ferrada, C
Salazar-Onfray, F
[J]. CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2005, 142 (03) : 555 - 568
[60] Immune Response in Patients With Newly Diagnosed Glioblastoma Multiforme Treated With Intranodal Autologous Tumor Lysate-dendritic Cell Vaccination After Radiation Chemotherapy
Fadul, Camilo E.
Fisher, Jan L.
Hampton, Thomas H.
Lallana, Enrico C.
Li, Zhongze
Gui, Jiang
Szczepiorkowski, Zbigniew M.
Tosteson, Tor D.
Rhodes, C. Harker
Wishart, Heather A.
Lewis, Lionel D.
Ernstoff, Marc S.
[J]. JOURNAL OF IMMUNOTHERAPY, 2011, 34 (04) : 382 - 389

← 1 2 3 4 5 6 7 8 9 10 →